The Use of a Vancomycin-Eluting Calcium Sulfate and Hydroxyapatite Composite for Dead Space Management in a Fracture-Related Infection (FRI): A Retrospective Case Series

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jun 17

PMID 38883114

Authors

Olivia Mair

Magdalena Bonleitner

Philipp Rittstieg

Peter Biberthaler

Marc Hanschen

Affiliations

Soon will be listed here.

Abstract

Background Cerament V (CV) is a bioactive bone graft substitute with vancomycin as an antimicrobial agent designed for the management of bone defects and infections. In this retrospective case series, we aim to evaluate the clinical outcomes of patients treated with CV for fracture-related infections (FRI). Methods All patients who received treatment for FRI and whose dead space and bone reconstruction management was solely done utilizing CV were included. The patients were recruited between September 2015 and September 2022. Data including patient demographics, primary diagnosis, surgical procedure, antibiotic therapy, microbiological results, complications, and follow-ups were recorded. Outcomes were assessed, including the percentage of bone void filling on radiographs, infection resolution, adverse effects, and patient-reported outcome measures by EQ-5D-5L. Results We present in this retrospective case series seven patients (three female) with a mean age of 56.86 ± 16.27 years. All patients underwent surgical debridement and bone grafting using CV. Antibiotic therapy was tailored to the specific pathogens isolated in each case. Infection eradication was achieved in five patients. On average, new bone formation was 81% at six months and 99% at 12 months. Patient-reported outcome parameters (PROMs) utilizing the EQ-5D-5L questionnaire were recorded at a mean follow-up of 42.00 ± 27.97 months with a median EQ-5D-5L index of 0.541 (range: 0.459 - 0.97) and a mean EQ-5D-Visual Analogue Scale (VAS) score of 62.20 ± 24.68. No major adverse events related to CV were reported. Conclusion This retrospective case series demonstrates the potential efficacy of CV in managing FRIs. The bioactive and antibiotic properties of CV appear to facilitate infection resolution and bone healing, with an advantageous safety profile. Larger prospective studies are needed to further investigate the utility of CV in orthopedic practice.

References

Govaert G, Kuehl R, Atkins B, Trampuz A, Morgenstern M, Obremskey W . Diagnosing Fracture-Related Infection: Current Concepts and Recommendations. J Orthop Trauma. 2019; 34(1):8-17. PMC: 6903359. DOI: 10.1097/BOT.0000000000001614. View

Ferguson J, Dudareva M, Riley N, Stubbs D, Atkins B, McNally M . The use of a biodegradable antibiotic-loaded calcium sulphate carrier containing tobramycin for the treatment of chronic osteomyelitis: a series of 195 cases. Bone Joint J. 2014; 96-B(6):829-36. DOI: 10.1302/0301-620X.96B6.32756. View

Hofmann A, Gorbulev S, Guehring T, Schulz A, Schupfner R, Raschke M . Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement for the Treatment of Bone Defects in Tibial Plateau Fractures: A Prospective, Randomized, Open-Label, Multicenter Study. J Bone Joint Surg Am. 2019; 102(3):179-193. PMC: 7508276. DOI: 10.2106/JBJS.19.00680. View

Depypere M, Kuehl R, Metsemakers W, Senneville E, McNally M, Obremskey W . Recommendations for Systemic Antimicrobial Therapy in Fracture-Related Infection: A Consensus From an International Expert Group. J Orthop Trauma. 2019; 34(1):30-41. PMC: 6903362. DOI: 10.1097/BOT.0000000000001626. View

Ferguson J, Diefenbeck M, McNally M . Ceramic Biocomposites as Biodegradable Antibiotic Carriers in the Treatment of Bone Infections. J Bone Jt Infect. 2017; 2(1):38-51. PMC: 5423569. DOI: 10.7150/jbji.17234. View

Kavarthapu V, Giddie J, Kommalapati V, Casey J, Bates M, Vas P . Evaluation of Adjuvant Antibiotic Loaded Injectable Bio-Composite Material in Diabetic Foot Osteomyelitis and Charcot Foot Reconstruction. J Clin Med. 2023; 12(9). PMC: 10179343. DOI: 10.3390/jcm12093239. View

Ferguson J, Bourget-Murray J, Stubbs D, McNally M, Hotchen A . A comparison of clinical and radiological outcomes between two different biodegradable local antibiotic carriers used in the single-stage surgical management of long bone osteomyelitis. Bone Joint Res. 2023; 12(7):412-422. PMC: 10317575. DOI: 10.1302/2046-3758.127.BJR-2022-0305.R2. View

Metsemakers W, Fragomen A, Moriarty T, Morgenstern M, Egol K, Zalavras C . Evidence-Based Recommendations for Local Antimicrobial Strategies and Dead Space Management in Fracture-Related Infection. J Orthop Trauma. 2019; 34(1):18-29. PMC: 6903381. DOI: 10.1097/BOT.0000000000001615. View

Pesch S, Hanschen M, Greve F, Zyskowski M, Seidl F, Kirchhoff C . Treatment of fracture-related infection of the lower extremity with antibiotic-eluting ceramic bone substitutes: case series of 35 patients and literature review. Infection. 2020; 48(3):333-344. PMC: 7256080. DOI: 10.1007/s15010-020-01418-3. View

10.

Cierny 3rd G, Mader J, Penninck J . A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003; (414):7-24. DOI: 10.1097/01.blo.0000088564.81746.62. View

11.

Metsemakers W, Morgenstern M, Senneville E, Borens O, Govaert G, Onsea J . General treatment principles for fracture-related infection: recommendations from an international expert group. Arch Orthop Trauma Surg. 2019; 140(8):1013-1027. PMC: 7351827. DOI: 10.1007/s00402-019-03287-4. View

12.

McNally M, Ferguson J, Scarborough M, Ramsden A, Stubbs D, Atkins B . Mid- to long-term results of single-stage surgery for patients with chronic osteomyelitis using a bioabsorbable gentamicin-loaded ceramic carrier. Bone Joint J. 2022; 104-B(9):1095-1100. PMC: 9948464. DOI: 10.1302/0301-620X.104B9.BJJ-2022-0396.R1. View

13.

Careri S, Vitiello R, Oliva M, Ziranu A, Maccauro G, Perisano C . Masquelet technique and osteomyelitis: innovations and literature review. Eur Rev Med Pharmacol Sci. 2019; 23(2 Suppl):210-216. DOI: 10.26355/eurrev_201904_17495. View

14.

OToole R, Joshi M, Carlini A, Murray C, Allen L, Huang Y . Effect of Intrawound Vancomycin Powder in Operatively Treated High-risk Tibia Fractures: A Randomized Clinical Trial. JAMA Surg. 2021; 156(5):e207259. DOI: 10.1001/jamasurg.2020.7259. View

15.

Auregan J, Begue T . Bioactive glass for long bone infection: a systematic review. Injury. 2016; 46 Suppl 8:S3-7. DOI: 10.1016/S0020-1383(15)30048-6. View

16.

Feng Y, Kohlmann T, Janssen M, Buchholz I . Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res. 2020; 30(3):647-673. PMC: 7952346. DOI: 10.1007/s11136-020-02688-y. View

17.

Rodham P, Panteli M, Qin C, Harwood P, Giannoudis P . Long-term outcomes of lower limb post-traumatic osteomyelitis. Eur J Trauma Emerg Surg. 2022; 49(1):539-549. PMC: 9925588. DOI: 10.1007/s00068-022-02104-9. View

18.

Ludwig K, von der Schulenburg J, Greiner W . German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018; 36(6):663-674. PMC: 5954069. DOI: 10.1007/s40273-018-0615-8. View

19.

Drampalos E, Mohammad H, Pillai A . Augmented debridement for implant related chronic osteomyelitis with an absorbable, gentamycin loaded calcium sulfate/hydroxyapatite biocomposite. J Orthop. 2019; 17:173-179. PMC: 6919360. DOI: 10.1016/j.jor.2019.08.017. View

20.

Metsemakers W, Morgenstern M, McNally M, Moriarty T, McFadyen I, Scarborough M . Fracture-related infection: A consensus on definition from an international expert group. Injury. 2017; 49(3):505-510. DOI: 10.1016/j.injury.2017.08.040. View